Medications Development for Cannabis-Related Disorder

The summary for the Medications Development for Cannabis-Related Disorder grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Medications Development for Cannabis-Related Disorder: The National Institute on Drug Abuse (NIDA) is seeking grant applications focusing on the identification, evaluation and development of safe and effective pharmacological treatments for cannabis-related disorders (CRDs), such as cannabis abuse or dependence, and cannabis- induced disorders (e.g., intoxication, delirium, psychotic disorder, and anxiety disorder), and their comorbidity with other medical and psychiatric disorders (e.g., depression), with special interest in the treatment of children and adolescents. Cannabis use includes marijuana, hashish, and other tetrahydrocannabinol (THC) containing substances. This RFA will support clinical trials to test potential medications in humans, and the preclinical development of new chemical entities (NCEs) for advancement to the clinical development stage. Applications may focus on the pharmacotherapy of cannabis abuse and they may target one or various CRDs or clinical manifestations of the disorders. For example, research may focus on marijuana dependence or specifically on marijuana withdrawal. Clinical applications may include human laboratory studies to develop models for testing medications targeting single or multiple manifestations of the CRDs, and the interaction of cannabinoids with other medications, pharmacokinetic and/or pharmacodynamic studies of potentially therapeutic compounds. Preclinical applications may include pharmacological studies on NCEs leading to the identification of candidates for advanced preclinical or phase I/II IND covered clinical evaluation as potential pharmacotherapies for CRDs.

Federal Grant Title:	Medications Development for Cannabis-Related Disorder
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health Education
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-04-014
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse Research Programs
Current Application Deadline:	No deadline provided
Original Application Deadline:	Mar 23, 2004
Posted Date:	Dec 08, 2003
Creation Date:	Apr 22, 2004
Archive Date:	Apr 22, 2004
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster
Similar Government Grants: • Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Interven...; • Neural Ensembles & Used Substances (NExUS) Collaboratory: Building a Multimodal Inventory ...; • Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Tr...; • Limited Competition: Growing Great Ideas: Research Education Course in Entrepreneurship an...; • Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional); • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinic...; • Immune Tolerance Network (UM1 Clinical Trial Required); • Coordinating Center for National Resource Network for the Study of Human Auditory and Vest...; • National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Cl...; • Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Interven...